{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:17:07Z","timestamp":1793881027682,"version":"4.7.0"},"reference-count":268,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T00:00:00Z","timestamp":1709942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Annually, more than 1.5 million preventable new hepatitis B (HBV) infections continue to occur, with an estimated global burden of 296 million individuals living with chronic hepatitis B infection. This substantial health challenge results in over 820,000 annual deaths being attributed to complications such as liver cirrhosis and hepatocellular carcinoma (HCC). The HBV vaccination remains the cornerstone of public health policy to prevent chronic hepatitis B and its related complications. It serves as a crucial element in the global effort to eliminate HBV, as established by the World Health Organization (WHO), with an ambitious 90% vaccination target by 2030. However, reports on global birth dose coverage reveal substantial variability, with an overall coverage rate of only 46%. This comprehensive review thoroughly examines global trends in HBV vaccination coverage, investigating the profound impact of vaccination on HBV prevalence and its consequences across diverse populations, including both high-risk and general demographics. Additionally, the review addresses the essential formidable challenges and facilitating factors for achieving WHO\u2019s HBV vaccination coverage objectives and elimination strategies in the coming decade and beyond.<\/jats:p>","DOI":"10.3390\/vaccines12030288","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T06:05:30Z","timestamp":1710137130000},"page":"288","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":119,"title":["Global Perspectives on the Hepatitis B Vaccination: Challenges, Achievements, and the Road to Elimination by 2030"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2741-0440","authenticated-orcid":false,"given":"Said A.","family":"Al-Busafi","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Alwassief","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Sultan Qaboos University Hospital, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.jhep.2015.01.018","article-title":"Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs","volume":"62","author":"Locarnini","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/B978-0-12-380888-2.00002-9","article-title":"Recent Advances in the Research of Hepatitis B Virus-Related Hepatocellular Carcinoma: Epidemiologic and Molecular Biological Aspects","volume":"108","author":"Kao","year":"2010","journal-title":"Adv. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: Incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM200205303462202","article-title":"Chronic hepatitis B","volume":"346","author":"Lok","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"1953","article-title":"Antibody level after hepatitis-B vaccination in hemodialysis patients: Impact of dialysis adequacy, chronic inflammation, local endemicity and nutritional status","volume":"98","author":"Ibrahim","year":"2006","journal-title":"J. Natl. Med. Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: A global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1001\/jama.1985.03350360066020","article-title":"Perinatal Hepatitis B Virus Transmission in the United States: Prevention by Passive-Active Immunization","volume":"253","author":"Stevens","year":"1985","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJM197504102921503","article-title":"Vertical transmission of hepatitis B antigen in Taiwan","volume":"292","author":"Stevens","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"ref_10","unstructured":"WHO (2021). Global Health Sector Strategies on HIV, Viral Hepatitis and the Sexually Transmitted Infections, World Health Organization. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2468-1253(23)00197-8","article-title":"Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: A modelling study","volume":"8","author":"Gamkrelidze","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40471-021-00273-6","article-title":"Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps","volume":"8","author":"Jaquet","year":"2021","journal-title":"Curr. Epidemiol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104675","DOI":"10.5812\/hepatmon.104675","article-title":"Association Between Income and Hepatitis B Seroprevalence: A Systematic Review and Meta-analysis","volume":"20","author":"Ding","year":"2020","journal-title":"Hepat. Mon."},{"key":"ref_14","unstructured":"(2024, January 16). Global Health Sector Strategy on Viral Hepatitis 2016\u20132021. Towards Ending Viral Hepatitis. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-HIV-2016.06."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Solomon-Rakiep, T., Olivier, J., and Amponsah-Dacosta, E. (2023). Weak Adoption and Performance of Hepatitis B Birth-Dose Vaccination Programs in Africa: Time to Consider Systems Complexity?\u2014A Scoping Review. Trop. Med. Infect. Dis., 8.","DOI":"10.20944\/preprints202308.1670.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/HEP.0000000000000430","article-title":"Pathway to global elimination of hepatitis B: HBV cure is just the first step","volume":"78","author":"Howell","year":"2023","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/hep.30899","article-title":"Modeling Progress Toward Elimination of Hepatitis B in Australia","volume":"71","author":"McCulloch","year":"2020","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.3748\/wjg.v24.i44.4959","article-title":"Hepatitis elimination by 2030: Progress and challenges","volume":"24","author":"Waheed","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s43066-023-00290-8","article-title":"The implications of the COVID-19 pandemic on hepatitis B and C elimination programs in Egypt: Current situation and future perspective","volume":"13","author":"Elsharkawy","year":"2023","journal-title":"Egypt. Liver J."},{"key":"ref_21","unstructured":"CDC (2023, December 23). Global Viral Hepatitis: Millions of People are Affected, Available online: https:\/\/www.cdc.gov\/hepatitis\/global\/index.htm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1136\/bmjgh-2020-002306","article-title":"Combating hepatitis B and C by 2030: Achievements, gaps, and options for actions in China","volume":"5","author":"Chen","year":"2020","journal-title":"BMJ Glob Health"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2468-1253(22)00386-7","article-title":"Global reporting of progress towards elimination of hepatitis B and hepatitis C","volume":"8","author":"Cui","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"(2021). Regional Consultation on the Global Health Sector Strategies on HIV, Hepatitis and STIs, 2022\u20132030. EMHJ, 27, 941\u2013942.","DOI":"10.26719\/2021.27.9.941"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/ID9.0000000000000028","article-title":"Elimination of Hepatitis by 2030: Present Realities and Future Projections","volume":"2","author":"Akbar","year":"2022","journal-title":"Infect. Dis. Immun."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1016\/j.ijid.2011.10.009","article-title":"Impact of the implementation of a vaccination strategy on hepatitis B virus infections in China over a 20-year period","volume":"16","author":"Luo","year":"2012","journal-title":"Int. J. Infect. Dis."},{"key":"ref_27","first-page":"447","article-title":"Review of Updated Hepatitis B Vaccine Recommendations and Potential Challenges with Implementation","volume":"18","author":"Chitnis","year":"2022","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1473-3099(02)00315-8","article-title":"Global control of hepatitis B virus infection","volume":"2","author":"Kao","year":"2002","journal-title":"Lancet Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/21645515.2020.1732166","article-title":"Hepatitis B vaccine development and implementation","volume":"16","author":"Zhao","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/jiv750","article-title":"Long-term Protection After Hepatitis B Vaccine","volume":"214","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0163-4453(83)96465-4","article-title":"The preparation and safety of hepatitis B vaccine","volume":"7","author":"Hilleman","year":"1983","journal-title":"J. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/jama.1986.03380070075022","article-title":"The Safety of the Hepatitis B Vaccine: Inactivation of the AIDS Virus During Routine Vaccine Manufacture","volume":"256","author":"Francis","year":"1986","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1001\/jama.1987.03390190090026","article-title":"Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission","volume":"257","author":"Stevens","year":"1987","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG Motifs in Bacterial DNA and Their Immune Effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0140-6736(85)92000-8","article-title":"Immunogenicity of recombinant yeast hepatitis B vaccine","volume":"325","author":"Davidson","year":"1985","journal-title":"Lancet"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(84)92740-5","article-title":"Clinical evaluation of a recombinant hepatitis B Vaccine","volume":"324","author":"Jilg","year":"1984","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S343","DOI":"10.1093\/infdis\/jiaa668","article-title":"Hepatitis B Vaccines","volume":"224","author":"Pattyn","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.vaccine.2014.12.060","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus","volume":"33","author":"Janssen","year":"2015","journal-title":"Vaccine"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1016\/j.vaccine.2013.05.067","article-title":"Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease","volume":"31","author":"Janssen","year":"2013","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1016\/j.vaccine.2012.02.001","article-title":"Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine","volume":"30","author":"Sablan","year":"2012","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM200102013440501","article-title":"Vaccinations and the Risk of Relapse in Multiple Sclerosis","volume":"344","author":"Hristian","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1212\/01.WNL.0000138433.61870.82","article-title":"Recombinant hepatitis B vaccine and the risk of multiple sclerosis: A prospective study","volume":"63","author":"Jick","year":"2004","journal-title":"Neurology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1086\/314578","article-title":"What level of hepatitis B antibody is protective?","volume":"179","author":"Jack","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.vaccine.2009.10.068","article-title":"Long-term protection provided by hepatitis B vaccine and need for booster dose: A meta-analysis","volume":"28","author":"Poorolajal","year":"2010","journal-title":"Vaccine"},{"key":"ref_45","unstructured":"(2024, January 19). Hepatitis B Vaccines: WHO Position Paper. Available online: https:\/\/www.who.int\/publications\/i\/item\/WER9227."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-8278(88)80032-1","article-title":"Persistence of specific antibodies after hepatitis B vaccination","volume":"6","author":"Jilg","year":"1988","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(84)92926-X","article-title":"Hepatitis B vaccination: How long does protection last?","volume":"2","author":"Jilg","year":"1984","journal-title":"Lancet"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.vaccine.2005.08.058","article-title":"Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination","volume":"24","author":"Bauer","year":"2006","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/cid\/ciu867","article-title":"Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults","volume":"60","author":"Gara","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.4254\/wjh.v7.i18.2127","article-title":"Three Decades of Hepatitis B Control with Vaccination","volume":"7","author":"Meireles","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/0264-410X(96)00062-X","article-title":"Vaccine Induced Immunologic Memory for Hepatitis B Surface Antigen: Implications for Policy on Booster Vaccination","volume":"14","author":"West","year":"1996","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.510290349","article-title":"Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen","volume":"29","author":"Huang","year":"1999","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.7326\/0003-4819-142-5-200503010-00008","article-title":"Antibody Levels and Protection after Hepatitis B Vaccination: Results of a 15-Year Follow-Up","volume":"142","author":"McMahon","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/cid\/cir270","article-title":"Hepatitis B and the need for a booster dose","volume":"53","author":"Plotkin","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2893.2003.00400.x","article-title":"Hepatitis B vaccine\u2014Do we need boosters?","volume":"10","author":"Banatvala","year":"2003","journal-title":"J. Viral Hepat."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/hep.23674","article-title":"Boosters for hepatitis B vaccination? Need for an evidence-based policy","volume":"51","author":"Hall","year":"2010","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/21645515.2019.1646575","article-title":"Long-term protection at 20\u201331 years after primary vaccination with plasma-derived hepatitis B vaccine in a Chinese rural community","volume":"16","author":"Ma","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.23543","article-title":"Determination of immune memory to hepatitis B vaccination through early booster response in college students","volume":"51","author":"Jan","year":"2010","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/S0140-6736(05)74663-8","article-title":"Hepatitis B booster vaccination for healthcare workers","volume":"355","author":"Yoshida","year":"2000","journal-title":"Lancet"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(05)73618-7","article-title":"Boosters for hepatitis B","volume":"356","author":"Banatvala","year":"2000","journal-title":"Lancet"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/0973-6247.33445","article-title":"Hepatitis B virus S gene escape mutants","volume":"1","author":"Purdy","year":"2007","journal-title":"Asian J. Transfus. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0140-6736(90)91874-A","article-title":"Vaccine-induced escape mutant of hepatitis B virus","volume":"336","author":"Carman","year":"1990","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/gut.2003.034223","article-title":"Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan","volume":"53","author":"Hsu","year":"2004","journal-title":"Gut"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1053\/jhep.2003.50484","article-title":"Deficiency in Virion Secretion and Decreased Stability of the Hepatitis B Virus Immune Escape Mutant G145R","volume":"38","author":"Kalinina","year":"2003","journal-title":"Hepatology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1086\/323396","article-title":"Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy","volume":"184","author":"Mele","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.jhep.2009.01.002","article-title":"Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B","volume":"50","author":"Chen","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hep.510300309","article-title":"Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus","volume":"30","author":"Ogata","year":"1999","journal-title":"Hepatology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"a021469","DOI":"10.1101\/cshperspect.a021469","article-title":"The Chimpanzee Model for Hepatitis B Virus Infection","volume":"5","author":"Wieland","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cld.2012.03.003","article-title":"Chronic Hepatitis B Infection","volume":"16","author":"Kuo","year":"2012","journal-title":"Clin. Liver Dis."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Inoue, T., and Tanaka, Y. (2020). Cross-Protection of Hepatitis B Vaccination among Different Genotypes. Vaccines, 8.","DOI":"10.3390\/vaccines8030456"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1056\/NEJMoa1007644","article-title":"Nucleic Acid Testing to Detect HBV Infection in Blood Donors","volume":"364","author":"Stramer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.21037\/aob.2017.04.02","article-title":"Chronic and occult hepatitis B virus infections in the vaccinated Chinese population","volume":"2","author":"Li","year":"2017","journal-title":"Ann. Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.3748\/wjg.v22.i13.3531","article-title":"Genetic variation of occult hepatitis B virus infection","volume":"22","author":"Zhu","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jhep.2008.09.017","article-title":"Occult hepatitis B virus infection in hepatitis B vaccinated children in Taiwan","volume":"50","author":"Mu","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2007.02.055","article-title":"Two Decades of Universal Hepatitis B Vaccination in Taiwan: Impact and Implication for Future Strategies","volume":"132","author":"Ni","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"27251","DOI":"10.1038\/srep27251","article-title":"Factors influencing immunologic response to hepatitis B vaccine in adults","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_77","unstructured":"(2024, January 20). Hepatitis B Foundation: Vaccine Non-Responders. Available online: https:\/\/www.hepb.org\/prevention-and-diagnosis\/vaccination\/vaccine-non-responders\/."},{"key":"ref_78","first-page":"492","article-title":"Immune response to anti-HBV vaccination: Study of conditioning factors","volume":"4","author":"Corrao","year":"1988","journal-title":"Epidemiology"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1086\/344271","article-title":"The Effect of Age on Immunologic Response to Recombinant Hepatitis B Vaccine: A Meta-analysis","volume":"35","author":"Fisman","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and Immunogenicity of 4 Intramuscular Double Doses and 4 Intradermal Low Doses vs Standard Hepatitis B Vaccine Regimen in Adults with HIV-1","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0264-410X(90)90037-M","article-title":"Response to intradermal hepatitis B vaccination: Differences between males and females?","volume":"8","author":"Senden","year":"1990","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0264-410X(89)90157-6","article-title":"Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination","volume":"7","author":"Shaw","year":"1989","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1086\/420740","article-title":"Hepatitis A and B Vaccination Practices for Ambulatory Patients Infected with HIV","volume":"38","author":"Tedaldi","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1289\/ehp.01109757","article-title":"Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors","volume":"109","author":"Vandebriel","year":"2001","journal-title":"Environ. Health Perspect."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0264-410X(94)90283-6","article-title":"Influence of smoking on immunological responses to hepatitis B vaccine","volume":"12","author":"Winter","year":"1994","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/infdis\/149.6.1019","article-title":"Hepatitis-B vaccination in the elderly","volume":"149","author":"Denis","year":"1984","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/0264-410X(94)90313-1","article-title":"Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers","volume":"12","author":"Heijtink","year":"1994","journal-title":"Vaccine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1016\/j.vaccine.2005.03.020","article-title":"Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules","volume":"23","author":"McNulty","year":"2005","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1053\/j.ajkd.2003.08.019","article-title":"Stage of Chronic Kidney Disease Predicts Seroconversion after Hepatitis B Immunization: Earlier is Better","volume":"42","author":"DaRoza","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1590\/S0004-28032004000300008","article-title":"Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus","volume":"41","author":"Gomes","year":"2004","journal-title":"Arq. Gastroenterol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.transproceed.2012.05.071","article-title":"Response to vaccination against hepatitis B virus with a schedule of four 40-\u03bcg doses in cirrhotic patients evaluated for liver transplantation: Factors associated with a response","volume":"44","year":"2012","journal-title":"Transplant. Proc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1086\/433180","article-title":"Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons","volume":"41","author":"Overton","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vaccine.2008.10.040","article-title":"Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients","volume":"27","author":"Cruciani","year":"2009","journal-title":"Vaccine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.vaccine.2012.01.064","article-title":"Hepatitis B virus vaccine in chronic kidney disease: Improved immunogenicity by adjuvants? A meta-analysis of randomized trials","volume":"30","author":"Fabrizi","year":"2012","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4254\/wjh.v7.i24.2503","article-title":"Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine","volume":"7","author":"Walayat","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e2128652","DOI":"10.1001\/jamanetworkopen.2021.28652","article-title":"Immunogenicity and Safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine: A Phase 3 Randomized Clinical Trial","volume":"4","author":"Vesikari","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e1942","DOI":"10.1002\/rmv.1942","article-title":"Response to hepatitis B vaccination in patients with liver cirrhosis","volume":"27","author":"Aggeletopoulou","year":"2017","journal-title":"Rev. Med. Virol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.3748\/wjg.v20.i30.10383","article-title":"Hepatitis B vaccine by intradermal route in non responder patients: An update","volume":"20","author":"Filippelli","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_100","unstructured":"Filippelli, M., Lionetti, E., Gennaro, A., Lanzafame, A., Arrigo, T., Salpietro, C., La Rosa, M., and Leonardi, S. (2023). HBV Vaccines: Advances and Development. Vaccines, 11."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/ajim.20230","article-title":"Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers","volume":"48","author":"Rapiti","year":"2005","journal-title":"Am. J. Ind. Med."},{"key":"ref_102","first-page":"276","article-title":"Hepatitis B immunization in healthcare workers","volume":"28","author":"Batra","year":"2015","journal-title":"Ann. Gastroenterol. Q. Publ. Hell. Soc. Gastroenterol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"ofy353","DOI":"10.1093\/ofid\/ofy353","article-title":"Cost-effectiveness of Hepatitis B Virus Infection Screening and Treatment or Vaccination in 6 High-risk Populations in the United States","volume":"6","author":"Peters","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1016\/j.vaccine.2023.04.022","article-title":"Cost-effectiveness of a 3-antigen versus single-antigen vaccine for the prevention of hepatitis B in adults in the United States","volume":"41","author":"Talbird","year":"2023","journal-title":"Vaccine"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1080\/21645515.2020.1845522","article-title":"Evaluating the cost-effectiveness of universal hepatitis B virus vaccination in Iran: A Markov model analysis","volume":"17","author":"Mokhtari","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.vaccine.2013.01.020","article-title":"Economic evaluation of universal newborn hepatitis B vaccination in China","volume":"31","author":"Lu","year":"2013","journal-title":"Vaccine"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1155\/2012\/736452","article-title":"Health state utilities and quality of life in patients with hepatitis B","volume":"26","author":"Woo","year":"2012","journal-title":"Can. J. Gastroenterol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.vaccine.2010.10.075","article-title":"Economic evaluation of infant and adolescent hepatitis B vaccination in the UK","volume":"29","author":"Siddiqui","year":"2011","journal-title":"Vaccine"},{"key":"ref_109","first-page":"E24","article-title":"Cost-effectiveness modelling of birth and infant dose vaccination against hepatitis B virus in Ontario from 2020 to 2050","volume":"11","author":"Biondi","year":"2023","journal-title":"Can. Med. Assoc. Open Access J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40249-022-01032-5","article-title":"Impact of the national hepatitis B immunization program in China: A modeling study","volume":"11","author":"Liu","year":"2022","journal-title":"Infect. Dis. Poverty"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1016\/j.vaccine.2021.07.100","article-title":"Considerations for estimating real-world outcomes and value in vaccination: A case study with adult hepatitis B virus vaccination","volume":"39","author":"Janssen","year":"2021","journal-title":"Vaccine"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.humimm.2020.02.010","article-title":"Assessment of a poly-epitope candidate vaccine against Hepatitis B, C, and poliovirus in interaction with monocyte-derived dendritic cells: An ex-vivo study","volume":"81","author":"Bahrami","year":"2020","journal-title":"Hum. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40005-019-00439-x","article-title":"Biocompatibility, biodegradation and biomedical applications of poly(lactic acid)\/poly(lactic-co-glycolic acid) micro and nanoparticles","volume":"49","author":"Elmowafy","year":"2019","journal-title":"J. Pharm. Investig."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14760584.2023.2229431","article-title":"Single administration vaccines: Delivery challenges, in vivo performance, and translational considerations","volume":"22","author":"Michaelides","year":"2023","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.addr.2015.03.007","article-title":"Delivery strategies to enhance oral vaccination against enteric infections","volume":"91","author":"Davitt","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.nano.2016.06.003","article-title":"Nanostructured SBA-15 silica: An effective protective vehicle to oral hepatitis B vaccine immunization","volume":"12","author":"Scaramuzzi","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.apsb.2019.05.003","article-title":"Pulmonary immunization: Deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination","volume":"9","author":"Tomar","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S2468-1253(18)30007-4","article-title":"Defective T-cell immunity in hepatitis B virus infection: Why therapeutic vaccination needs a helping hand","volume":"3","author":"Maini","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1172\/JCI121960","article-title":"Circulating and intrahepatic antiviral B cells are defective in hepatitis B","volume":"128","author":"Burton","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Horng, J.-H., Lin, W.-H., Wu, C.-R., Lin, Y.-Y., Wu, L.-L., Chen, D.-S., and Chen, P.-J. (2020). HBV X protein-based therapeutic vaccine accelerates viral antigen clearance by mobilizing monocyte infiltration into the liver in HBV carrier mice. J. Biomed. Sci., 27.","DOI":"10.1186\/s12929-020-00662-x"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Zheng, J., Lin, X., Wang, X., Zheng, L., Lan, S., Jin, S., Ou, Z., and Wu, J. (2017). In Silico Analysis of Epitope-Based Vaccine Candidates against Hepatitis B Virus Polymerase Protein. Viruses, 9.","DOI":"10.3390\/v9050112"},{"key":"ref_122","first-page":"10069","article-title":"Personalised Vaccination Prediction for Hepatitis B using Machine Learning","volume":"25","author":"Vijayalakshmi","year":"2021","journal-title":"Ann. Rom. Soc. Cell Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"690470","DOI":"10.3389\/fimmu.2021.690470","article-title":"Machine Learning-Based Single Cell and Integrative Analysis Reveals That Baseline mDC Predisposition Correlates with Hepatitis B Vaccine Antibody Response","volume":"12","author":"Aevermann","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1001\/jama.1990.03440090052025","article-title":"The Changing Epidemiology of Hepatitis B in the United States: Need for Alternative Vaccination Strategies","volume":"263","author":"Alter","year":"1990","journal-title":"JAMA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1988.03720030025027","article-title":"Cost-effectiveness of Prenatal Screening and Immunization for Hepatitis B Virus","volume":"259","author":"Arevalo","year":"1988","journal-title":"JAMA"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/jama.1987.03390190075023","article-title":"A Mass Vaccination Program in Taiwan Against Hepatitis B Virus Infection in Infants of Hepatitis B Surface Antigen\u2014Carrier Mothers","volume":"257","author":"Chen","year":"1987","journal-title":"JAMA"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1136\/bmj.314.7086.1033","article-title":"Integration of Hepatitis B Vaccination into National Immunisation Programmes","volume":"314","author":"Meheus","year":"1997","journal-title":"BMJ"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/infdis\/171.2.290","article-title":"Lombok Hepatitis B Model Immunization Project: Toward universal infant hepatitis B immunization in Indonesia","volume":"171","author":"Ruff","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0140-6736(93)93137-P","article-title":"Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation","volume":"341","author":"Fortuin","year":"1993","journal-title":"Lancet"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/j.1440-1746.2008.05584.x","article-title":"Does the level of hepatitis B virus vaccination in health-care workers need improvement?","volume":"23","author":"Acharya","year":"2008","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(81)92679-9","article-title":"Randomised placebo-controlled trial of hepatitis b surface antigen vaccine in french haemodialysis units: II, haemodialysis patients","volume":"317","author":"Crosnier","year":"1981","journal-title":"Lancet"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1056\/NEJM198212093072403","article-title":"Hepatitis B Vaccine in Medical Staff of Hemodialysis Units: Efficacy and Subtype Cross-Protection","volume":"307","author":"Crosnier","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJM198408233110803","article-title":"Hepatitis B Vaccine in Patients Receiving Hemodialysis: Immunogenicity and Efficacy","volume":"311","author":"Stevens","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nep.13741","article-title":"Vaccination in patients with chronic kidney disease\u2014Review of current recommendations and recent advances","volume":"26","author":"Ma","year":"2021","journal-title":"Nephrology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nefro.2020.08.016","article-title":"Hepatitis B virus vaccine and chronic kidney disease","volume":"41","author":"Fabrizi","year":"2021","journal-title":"The advances. Nefrologia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.5812\/hepatmon.7359","article-title":"Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients","volume":"12","author":"Grzegorzewska","year":"2012","journal-title":"Hepat. Mon."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3949\/ccjm.85a.17017","article-title":"What is the hepatitis B vaccination regimen in chronic kidney disease?","volume":"85","author":"Ong","year":"2018","journal-title":"Cleve Clin. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0168-8278(05)80327-7","article-title":"Increasing serum creatinine and age reduce the response to hepatitis B vaccine in renal failure patients","volume":"21","author":"Faser","year":"1994","journal-title":"J. Hepatol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s40620-019-00668-1","article-title":"Hepatitis B virus vaccine immune response and mortality in dialysis patients: A meta-analysis","volume":"33","author":"Udomkarnjananun","year":"2020","journal-title":"J. Nephrol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000065873","article-title":"Efficient haemodialysis improves the response to hepatitis B virus vaccination","volume":"45","author":"Kovacic","year":"2002","journal-title":"Intervirology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s11255-017-1616-9","article-title":"Factors affecting responsiveness to hepatitis B immunization in dialysis patients","volume":"49","author":"Asan","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"ref_142","first-page":"109","article-title":"Hemodialysis and hepatitis B vaccination: A challenge to physicians","volume":"7","author":"Ayub","year":"2014","journal-title":"Int. J. Gen. Med."},{"key":"ref_143","first-page":"143","article-title":"Hepatitis B vaccine: Randomized trial of immunogenicity in hemodialysis patients","volume":"21","author":"Benhamou","year":"1984","journal-title":"Clin. Nephrol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/pmj.78.923.538","article-title":"Vaccination against hepatitis B infection in patients with end stage renal disease","volume":"78","author":"Wright","year":"2002","journal-title":"Postgrad. Med. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"960413","DOI":"10.5402\/2012\/960413","article-title":"Improving Hepatitis B Vaccine Efficacy in End-Stage Renal Diseases Patients and Role of Adjuvants","volume":"2012","author":"Somi","year":"2012","journal-title":"ISRN Gastroenterol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1111\/ajt.13380","article-title":"Comparing Humoral and Cellular Immune Response Against HBV Vaccine in Kidney Transplant Patients","volume":"15","author":"Friedrich","year":"2015","journal-title":"Am. J. Transplant."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4254\/wjh.v9.i25.1054","article-title":"Hepatitis B in renal transplant patients","volume":"9","author":"Marinaki","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.3748\/wjg.v20.i34.12018","article-title":"Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients","volume":"20","author":"Eleftheriadis","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0264-410X(93)90278-6","article-title":"Broe Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients","volume":"11","author":"Lefebure","year":"1993","journal-title":"Vaccine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/j.1365-2036.2004.02264.x","article-title":"Meta-analysis: The effect of age on immunological response to hepatitis B vaccine in end-stage renal disease","volume":"20","author":"Fabrizi","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/0002-9343(89)90526-3","article-title":"Vaccination against hepatitis B in homosexual men: A review","volume":"87","author":"Goilav","year":"1989","journal-title":"Am. J. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1056\/NEJM198010093031501","article-title":"Hepatitis B Vaccine: Demonstration of Efficacy in a Controlled Clinical Trial in a High-Risk Population in the United States","volume":"303","author":"Szmuness","year":"1980","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1001\/jama.1988.03410240105040","article-title":"Comparative Immunogenicity of Plasma and Recombinant Hepatitis B Virus Vaccines in Homosexual Men","volume":"260","author":"Odaka","year":"1988","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/0003-4819-97-3-362","article-title":"The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men","volume":"97","author":"Francis","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0956462415613726","article-title":"Factors associated with hepatitis B vaccination among men who have sex with men: A systematic review of published research","volume":"28","author":"Vet","year":"2015","journal-title":"Int. J. STD AIDS"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Francis, D.P., Hadler, S.C., Thompson, S.E., Maynard, J.E., Ostrow, D.G., Altman, N., Braff, E.H., O\u2019Malley, P., Hawkins, D., and Judson, F.N. (2017). Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco. BMC Public Health, 17.","DOI":"10.1186\/s12889-017-4776-8"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/21645515.2016.1277844","article-title":"Hepatitis B virus vaccination in HIV-infected people: A review","volume":"13","author":"Catherine","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1468-1293.2008.00598.x","article-title":"Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania","volume":"9","author":"Pippi","year":"2008","journal-title":"HIV Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/0264-410X(92)90050-T","article-title":"Impaired response to hepatitis B vaccine in HIV infected children","volume":"10","author":"Zuin","year":"1992","journal-title":"Vaccine"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.amjmed.2005.07.024","article-title":"Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus","volume":"118","author":"Laurence","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/00365540701522975","article-title":"Immunological response to hepatitis B vaccination in patients with AIDS and virological response to highly active antiretroviral therapy","volume":"40","author":"Paitoonpong","year":"2008","journal-title":"Scand. J. Infect. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.aohep.2019.03.012","article-title":"Evaluation of response to hepatitis B virus vaccine in adults with human immunodeficiency virus","volume":"18","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e2121281","DOI":"10.1001\/jamanetworkopen.2021.21281","article-title":"Hepatitis B Vaccination in People Living With HIV\u2014If at First You Don\u2019t Succeed, Try Again","volume":"4","author":"Mohareb","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/08971900221078742","article-title":"Efficacy of Hepatitis B Vaccine in Adults with Chronic Liver Disease","volume":"36","author":"Kim","year":"2022","journal-title":"J. Pharm. Pract."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"196704","DOI":"10.1155\/2013\/196704","article-title":"Safety and efficacy of hepatitis B vaccination in cirrhosis of liver","volume":"2013","author":"Roni","year":"2013","journal-title":"Adv. Virol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1365-2036.2004.01906.x","article-title":"Hepatitis vaccination in patients with chronic liver disease","volume":"19","author":"Reiss","year":"2004","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Horta, D., Forn\u00e9, M., Agust\u00ed, A., Raga, A., Mart\u00edn-Cardona, A., Hern\u00e1ndez-Soto, J.M., Ruiz-Ram\u00edrez, P., and Esteve-Comas, M. (2022). Efficacy of Hepatitis B Virus Vaccines HBVaxpro40\u00a9 and Fendrix\u00a9 in Patients with Chronic Liver Disease in Clinical Practice. Vaccines, 10.","DOI":"10.3390\/vaccines10081323"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"198953","DOI":"10.1016\/j.virusres.2022.198953","article-title":"Clinical study on the efficacy of hepatitis B vaccination in hepatitis C virus related chronic liver diseases in Egypt","volume":"323","author":"Hassnine","year":"2023","journal-title":"Virus Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF01535747","article-title":"Hepatitis B vaccination\u2014Response of alcoholic with and without liver injury","volume":"33","author":"Mendenhall","year":"1988","journal-title":"Dig. Dis. Sci."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S0168-8278(86)80051-4","article-title":"Hepatitis B vaccination in chronic alcoholics","volume":"2","author":"Degos","year":"1986","journal-title":"J. Hepatol."},{"key":"ref_171","first-page":"169","article-title":"Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation","volume":"43","author":"Pascasio","year":"2020","journal-title":"Gastroenterol. Hepatol. (Engl. Ed.)"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"17494","DOI":"10.3390\/ijms160817494","article-title":"Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence","volume":"16","author":"Takaki","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"150","DOI":"10.14218\/JCTH.2020.00003","article-title":"Prevention of HBV Recurrence after Liver Transplant: A Review","volume":"8","author":"Nasir","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"12083","DOI":"10.3748\/wjg.v21.i42.12083","article-title":"Management of hepatitis B virus infection after liver transplantation","volume":"21","author":"Torres","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/lt.23935","article-title":"Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients","volume":"20","author":"Ishigami","year":"2014","journal-title":"Liver Transplant."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1016\/j.transproceed.2021.09.038","article-title":"Efficacy and Safety of Hepatitis B Virus Vaccination Following Hepatitis B Immunoglobulin Withdrawal After Liver Transplantation","volume":"53","author":"Jo","year":"2021","journal-title":"Transplant. Proc."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1590\/s0004-2803.201900000-77","article-title":"New immunization schedule effectiveness against hepatitis B in liver transplantation patients","volume":"56","author":"Rodrigues","year":"2019","journal-title":"Arq. Gastroenterol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cld.2016.06.004","article-title":"The Management of Hepatitis B in Liver Transplant Recipients","volume":"20","author":"Saab","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_179","unstructured":"(2024, January 17). Global Hepatitis Report. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241565455."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S2468-1253(18)30199-7","article-title":"Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission\u2014Authors\u2019 reply","volume":"3","author":"Razavi","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cld.1096","article-title":"Prevention of Mother-to-Child Transmission of Hepatitis B Virus in the Western Pacific Region","volume":"18","author":"Shan","year":"2021","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/1097-0142(19891201)64:11<2377::AID-CNCR2820641130>3.0.CO;2-8","article-title":"Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma","volume":"64","author":"Chang","year":"1989","journal-title":"Cancer"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.biologicals.2017.08.008","article-title":"Eradicating hepatitis B virus: The critical role of preventing perinatal transmission","volume":"50","author":"Stevens","year":"2017","journal-title":"Biologicals"},{"key":"ref_184","first-page":"85","article-title":"Immunogenicity and efficacy of a recombinant DNA hepatitis B vaccine, GenHevac B Pasteur in high risk neonates, school children and healthy adults","volume":"11","author":"Assateerawatt","year":"1993","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1001\/jama.1989.03420220092033","article-title":"Protective Efficacy of a Recombinant DNA Hepatitis B Vaccine in Neonates of HBe Antigen\u2014Positive Mothers","volume":"261","author":"Poovorawan","year":"1989","journal-title":"JAMA"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jmv.10071","article-title":"Field evaluation of the efficacy and immunogenicity of recombinant hepatitis B vaccine without HBIG in newborn Vietnamese infants","volume":"67","author":"Milne","year":"2002","journal-title":"J. Med. Virol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1097\/INF.0000000000001578","article-title":"Serologic Responses after Hepatitis B Vaccination in Preterm Infants Born to Hepatitis B Surface Antigen-Positive Mothers: Singapore Experience","volume":"36","author":"Tan","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"100076","DOI":"10.1016\/j.jve.2022.100076","article-title":"Efficacy of the hepatitis B vaccine alone in the prevention of hepatitis B perinatal transmission in infants born to hepatitis B e antigen-negative carrier mothers","volume":"8","author":"Zhang","year":"2022","journal-title":"J. Virus Erad."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0264-410X(00)00216-4","article-title":"Impact of hepatitis B immunisation as part of the EPI","volume":"19","author":"Poovorawan","year":"2000","journal-title":"Vaccine"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1542\/peds.90.1.170","article-title":"Prospects for Control of Hepatitis B Virus Infection: Implications of Childhood Vaccination and Long-term Protection","volume":"90","author":"Stevens","year":"1992","journal-title":"Pediatrics"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.1988.03410150079034","article-title":"Efficacy of a Mass Hepatitis B Vaccination Program in Taiwan: Studies on 3464 Infants of Hepatitis B Surface Antigen\u2014Carrier Mothers","volume":"260","author":"Hsu","year":"1988","journal-title":"JAMA"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/infdis\/170.6.1418","article-title":"Outcome of perinatal hepatitis b virus exposure is dependent on maternal virus load","volume":"170","author":"Burk","year":"1994","journal-title":"J. Infect. Dis."},{"key":"ref_193","first-page":"379","article-title":"HBsAg level and hepatitis B viral load correlation with focus on pregnancy","volume":"28","author":"Belopolskaya","year":"2015","journal-title":"Ann. Gastroenterol. Q. Publ. Hell. Soc. Gastroenterol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.28589","article-title":"Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection","volume":"64","author":"Wen","year":"2016","journal-title":"Hepatology"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1016\/j.vaccine.2012.06.036","article-title":"A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women","volume":"30","author":"Sun","year":"2012","journal-title":"Vaccine"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1056\/NEJMoa1508660","article-title":"Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load","volume":"374","author":"Pan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_198","unstructured":"(2024, January 12). Hepatitis B Is Preventable with Safe and Effective Vaccines. Available online: https:\/\/www.who.int\/southeastasia\/activities\/hepatitis-b-is-preventable-with-safe-and-effective-vaccines."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"a021493","DOI":"10.1101\/cshperspect.a021493","article-title":"Prevention of Hepatitis B","volume":"5","author":"Chang","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_200","unstructured":"(2024, January 16). Immunization Coverage. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/immunization-coverage."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kjms.2011.10.027","article-title":"Towards the eradication of hepatitis B in Taiwan","volume":"28","author":"Wait","year":"2012","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/jama.2013.276701","article-title":"Thirty-Year Outcomes of the National Hepatitis B Immunization Program in Taiwan","volume":"310","author":"Chiang","year":"2013","journal-title":"JAMA"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jhep.2012.05.021","article-title":"Minimization of hepatitis B infection by a 25-year universal vaccination program","volume":"57","author":"Ni","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1086\/314585","article-title":"Seroepidemiologic survey for hepatitis B virus infection in Taiwan: The effect of hepatitis B mass immunization","volume":"179","author":"Hsu","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.bjid.2019.10.001","article-title":"The effectiveness of the national hepatitis B vaccination program 25 years after its introduction in Iran: A historical cohort study","volume":"23","author":"Moghadami","year":"2019","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.vaccine.2017.11.027","article-title":"Status and progress of hepatitis B control through vaccination in the South-East Asia Region, 1992\u20132015","volume":"36","author":"Childs","year":"2018","journal-title":"Vaccine"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.siny.2007.01.013","article-title":"Hepatitis B virus infection","volume":"12","author":"Chang","year":"2007","journal-title":"Semin. Fetal Neonatal Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1016\/S0264-410X(02)00358-4","article-title":"Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand","volume":"20","author":"Lolekha","year":"2002","journal-title":"Vaccine"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.cld.2016.06.006","article-title":"Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease","volume":"20","author":"Nelson","year":"2016","journal-title":"Clin. Liver Dis."},{"key":"ref_210","unstructured":"CDC (2024, January 13). Pinkbook: Hepatitis B, Available online: https:\/\/www.cdc.gov\/vaccines\/pubs\/pinkbook\/hepb.html."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mpd.2001.116277","article-title":"Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan","volume":"139","author":"Kao","year":"2001","journal-title":"J. Pediatr."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.20006","article-title":"Pediatric fulminant hepatic failure in endemic areas of hepatitis B infection: 15 years after universal hepatitis B vaccination","volume":"39","author":"Chen","year":"2004","journal-title":"Hepatology"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1086\/528687","article-title":"Acute hepatitis B 14 years after the implementation of universal vaccination in Italy: Areas of improvement and emerging challenges","volume":"46","author":"Mele","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1086\/510433","article-title":"Acute hepatitis delta virus infection in Italy: Incidence and risk factors after the introduction of the universal anti-hepatitis B vaccination campaign","volume":"44","author":"Mele","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_215","first-page":"671","article-title":"Prevention and control of hepatitis B virus infection in Singapore","volume":"26","author":"Goh","year":"1997","journal-title":"Ann. Acad. Med. Singap."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archpedi.157.10.1025","article-title":"The impact of the hepatitis B virus vaccine on the incidence of hepatitis B virus-associated membranous nephropathy","volume":"157","author":"Bhimma","year":"2003","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1007\/s00467-003-1277-z","article-title":"The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis","volume":"18","author":"Xu","year":"2003","journal-title":"Pediatr. Nephrol."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1542\/peds.2010-3137","article-title":"Universal Hepatitis B Vaccination Reduces Childhood Hepatitis B Virus\u2013Associated Membranous Nephropathy","volume":"128","author":"Liao","year":"2011","journal-title":"Pediatrics"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199706263362602","article-title":"Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group","volume":"336","author":"Chang","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"855945","DOI":"10.3389\/fonc.2022.855945","article-title":"Accelerating Decreases in the Incidences of Hepatocellular Carcinoma at a Younger Age in Shanghai Are Associated with Hepatitis B Virus Vaccination","volume":"12","author":"Yu","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Flores, J.E., Thompson, A.J., Ryan, M., and Howell, J. (2022). The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines, 10.","DOI":"10.3390\/vaccines10050793"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.trstmh.2005.12.003","article-title":"Trend in incidence of hepatitis B virus infection during a decade of universal childhood hepatitis B vaccination in Saudi Arabia","volume":"101","author":"Madani","year":"2007","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_223","first-page":"385","article-title":"Efficacy of hepatitis B vaccination on hepatitis B prevention and on hepatocellular carcinoma","volume":"25","author":"Li","year":"2004","journal-title":"Zhonghua Liu Xing Bing Xue Za Zhi"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/ije\/27.2.316","article-title":"Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: A cohort study in Korea","volume":"27","author":"Lee","year":"1998","journal-title":"Int. J. Epidemiol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019","volume":"7","author":"Sheena","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2471\/BLT.16.178822","article-title":"Hepatitis B vaccination timing: Results from demographic health surveys in 47 countries","volume":"95","author":"Schweitzer","year":"2017","journal-title":"Bull. World Health Organ."},{"key":"ref_227","unstructured":"Center for Global Development (2024, January 25). Vaccine Introduction and Coverage in Gavi-Supported Countries 2015\u20132018: Implications for Gavi 5.0. Available online: https:\/\/www.cgdev.org\/publication\/vaccine-introduction-and-coverage-gavi-supported-countries-2015-2018-implications-gavi."},{"key":"ref_228","first-page":"29","article-title":"Implementing and Understanding Barriers to the Updated Hepatitis B Vaccination Recommendations and Guidance","volume":"30","author":"BIGHAM","year":"2023","journal-title":"Fam. Pract. Manag."},{"key":"ref_229","doi-asserted-by":"crossref","unstructured":"Machmud, P.B., F\u00fchrer, A., Gottschick, C., and Mikolajczyk, R. (2023). Barriers to and Facilitators of Hepatitis B Vaccination among the Adult Population in Indonesia: A Mixed Methods Study. Vaccines, 11.","DOI":"10.3390\/vaccines11020398"},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Freeland, C., Kanu, F., Mohammed, Y., Nwokoro, U.U., Sandhu, H., Ikwe, H., Uba, B., Asekun, A., Akataobi, C., and Adewole, A. (2023). Barriers and facilitators to hepatitis B birth dose vaccination: Perspectives from healthcare providers and pregnant women accessing antenatal care in Nigeria. PLOS Global Public Health, 3.","DOI":"10.1371\/journal.pgph.0001332"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.31557\/APJCP.2020.21.12.3453","article-title":"Vaccination against Hepatitis B: A Scoping Review","volume":"21","author":"Mohanty","year":"2020","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Ali, A.S., Hussein, N.A., Elmi, E.O.H., Ismail, A.M., and Abdi, M.M. (2023). Hepatitis B vaccination coverage and associated factors among medical students: A cross-sectional study in Bosaso, Somalia, 2021. BMC Public Health, 23.","DOI":"10.1186\/s12889-023-15992-2"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhepr.2019.04.002","article-title":"Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017","volume":"1","author":"Smith","year":"2019","journal-title":"JHEP Rep"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"ref_235","unstructured":"Hepatitis, B. (2024, January 16). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_236","unstructured":"(2024, January 29). The Global Hepatitis Health Sector Strategy\u2014Global 2017, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK442270\/."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1056\/NEJMra1810477","article-title":"Global Elimination of Chronic Hepatitis","volume":"380","author":"Thomas","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S2468-1253(18)30270-X","article-title":"Accelerating the elimination of viral hepatitis: A Lancet Gastroenterology & Hepatology Commission","volume":"4","author":"Cooke","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: Eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bull. World Health Organ."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study","volume":"3","author":"Gamkrelidze","year":"2018","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/jvh.13231","article-title":"Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world?","volume":"27","author":"Nayagam","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/liv.14222","article-title":"Innovative strategies for the elimination of viral hepatitis at a national level: A country case series","volume":"39","author":"Pedrana","year":"2019","journal-title":"Liver Int."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1016\/S2214-109X(19)30272-4","article-title":"Additional resource needs for viral hepatitis elimination through universal health coverage: Projections in 67 low-income and middle-income countries, 2016\u20132030","volume":"7","author":"Tordrup","year":"2019","journal-title":"Lancet Glob. Health"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/liv.14324","article-title":"Global timing of hepatitis C virus elimination in high-income countries","volume":"40","author":"Razavi","year":"2020","journal-title":"Liver Int."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2468-1253(20)30011-X","article-title":"Do the most heavily burdened countries have the right policies to eliminate viral hepatitis B and C?","volume":"5","author":"Palayew","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"100531","DOI":"10.1016\/j.jhepr.2022.100531","article-title":"Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey","volume":"4","author":"Kondili","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/aid.2020.0301","article-title":"Impact of Coronavirus Disease 2019 Pandemic on Viral Hepatitis Elimination: What Is the Price?","volume":"37","author":"Sowah","year":"2021","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/cld.1088","article-title":"Impact of COVID-19 Response on Hepatitis Prevention Care and Treatment: Results from Global Survey of Providers and Program Managers","volume":"17","author":"Laury","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_250","first-page":"670","article-title":"Introduction to the Special Issue on \u2018The World Health Organization Choosing Interventions That Are Cost-Effective (WHO-CHOICE) Update\u2019","volume":"10","author":"Bertram","year":"2021","journal-title":"Int. J. Health Policy Manag."},{"key":"ref_251","unstructured":"(2024, February 03). Consolidated Strategic Information Guidelines for Viral Hepatitis Planning and Tracking Progress towards Elimination: Guidelines. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789241515191."},{"key":"ref_252","unstructured":"(2024, February 03). New Cost-Effectiveness Updates from WHO-CHOICE. Available online: https:\/\/www.who.int\/news-room\/feature-stories\/detail\/new-cost-effectiveness-updates-from-who-choice."},{"key":"ref_253","unstructured":"(2024, February 03). Hepatitis WPRO. Available online: https:\/\/www.who.int\/westernpacific\/health-topics\/hepatitis#tab=tab_1."},{"key":"ref_254","unstructured":"Gavi, the Vaccine Alliance (2024, January 16). From Rabies to Hepatitis: Gavi to Start Rolling out New Vaccines to Lower-Income Countries. Available online: https:\/\/www.gavi.org\/vaccineswork\/kickstarting-essential-immunisation-roll-outs."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-na\u00efve patients with chronic hepatitis B in Korea: A large-scale, propensity score analysis","volume":"69","author":"Lee","year":"2020","journal-title":"Gut"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/apt.13694","article-title":"Review article: Novel therapies for hepatitis B virus cure\u2014Advances and perspectives","volume":"44","author":"Lin","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_257","first-page":"1070","article-title":"Guidance for design and endpoints of clinical trials in chronic hepatitis B\u2014Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference","volume":"71","author":"Lee","year":"2019","journal-title":"Hepatology"},{"key":"ref_258","unstructured":"(2024, February 02). Polaris Observatory\u2014CDA Foundation. Available online: https:\/\/cdafound.org\/polaris\/."},{"key":"ref_259","unstructured":"Coalition for Global Hepatitis Elimination (2024, February 03). The Hepatitis Prevention, Control, and Elimination Program in Mongolia\u2014\u042d\u043b\u044d\u0433 \u0431\u04af\u0442\u044d\u043d \u041c\u043e\u043d\u0433\u043e\u043b \u04af\u043d\u0434\u044d\u0441\u043d\u0438\u0439 \u0445\u0473\u0442\u0473\u043b\u0431\u0473\u0440 (National Program). Available online: https:\/\/www.globalhep.org\/about\/partner-programs\/hepatitis-prevention-control-and-elimination-program-mongolia-eleg-buten."},{"key":"ref_260","unstructured":"(2024, February 04). Find the Missing Millions\u2014World Hepatitis Alliance. Available online: https:\/\/www.worldhepatitisalliance.org\/find-the-missing-millions\/."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"76","DOI":"10.7326\/M14-1153","article-title":"Screening for hepatitis B virus infection: A public health imperative","volume":"161","author":"Rajbhandari","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1186\/s12889-023-17263-6","article-title":"Experience and impact of stigma in people with chronic hepatitis B: A qualitative study in Asia, Europe, and the United States","volume":"24","author":"Toumi","year":"2024","journal-title":"BMC Public Health"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/infdis\/jiac446","article-title":"HCV Microelimination for High-risk Special Populations","volume":"228","author":"Huang","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_264","first-page":"e14657","article-title":"Challenges in Formulation and Implementation of Hepatitis B Elimination Programs","volume":"13","author":"Abbas","year":"2021","journal-title":"Cureus"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1016\/S2214-109X(16)30130-9","article-title":"Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: The Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study","volume":"4","author":"Lemoine","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jhep.2020.09.013","article-title":"A global investment framework for the elimination of hepatitis B","volume":"74","author":"Howell","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.24500","article-title":"Fighting against viral hepatitis: Lessons from Taiwan","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/288\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:11:28Z","timestamp":1760105488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/3\/288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,9]]},"references-count":268,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["vaccines12030288"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12030288","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,9]]}}}